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ABSTRACT
Objectives Long-term safety and efficacy of
adalimumab among patients with juvenile idiopathic
arthritis (JIA) was evaluated through 6 years of
treatment.
Methods Children aged 4–17 years with polyarticular
JIA were enrolled in a phase III, randomised-
withdrawal, double-blind, placebo-controlled trial
consisting of a 16-week open-label lead-in period, 32-
week randomised double-blind period and 360-week
long-term extension. Patients were stratified by
baseline methotrexate use. Adverse events (AEs) were
monitored, and efficacy assessments included JIA
American College of Rheumatology (JIA ACR) 30%,
50%, 70% or 90% responses and the proportions of
patients achieving 27-joint Juvenile Arthritis Disease
Activity Score (JADAS27) low disease activity (LDA,
≤3.8) and inactive disease (ID, ≤1).
Results Of 171 patients enrolled, 62 (36%) completed
the long-term extension. Twelve serious infections in 11
patients were reported through 592.8 patient-years of
exposure. No cases of congestive heart failure-related
AEs, demyelinating disease, lupus-like syndrome,
malignancies, tuberculosis or deaths were reported. JIA
ACR 30/50/70/90 responses and JADAS27 LDA were
achieved in 66% to 96% of patients at week 104, and
63 (37%) patients achieved clinical remission (JADAS27
ID sustained for ≥6 continuous months) during the
study. Attainment of JIA ACR 50 or higher and JADAS27
LDA or ID in the initial weeks were the best predictors
of clinical remission. Mean JADAS27 decreased from
baseline, 22.5 (n=170), to 2.5 (n=30) at week 312
(observed analysis).
Conclusions Through 6 years of exposure,
adalimumab was well tolerated with significant clinical
response (up to clinical remission) and a relatively low
retention rate.
INTRODUCTION
Juvenile idiopathic arthritis (JIA) describes
a clinically heterogeneous group of arthri-
tides of unknown cause that begin before
16 years of age and often continue into
adulthood.1–3 The American College of
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What is already known about this subject?
► Adalimumab has a favourable benefit–risk profile in
children with JIA, but extended long-term safety and
efficacy outcomes and predictors of sustained
disease control have not been previously assessed.
What does this study add?
► This study investigated the long-term safety and
efficacy of adalimumab, and demonstrated that
adalimumab was well tolerated and effective among
children with polyarticular JIA through 6 years of
exposure with or without background methotrexate
therapy.
► The study results also indicated that early clinical
response predicted achievement of JADAS27 clinical
remission.
How might this impact on clinical practice or
future developments?
► These results support the long-term use of
adalimumab as a therapy option for patients with
active polyarticular JIA.
► Furthermore, early response to treatment was shown
to be associated with disease remission in patients
with JIA, suggesting that therapy adjustments are
warranted early in patients who fail to respond.
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Rheumatology (ACR) recommendations suggest initiat-
ing treatment with non-steroidal anti-inflammatory drugs
(NSAIDs) or methotrexate or, in more severe cases,
biologics.4 Because use of a particular biological agent
in an individual patient may be limited by long-term
toxicity, inadequate response or the inability to maintain
an acceptable level of disease control, it is important to
have knowledge and regulatory approval of several biolo-
gical therapies for the treatment of JIA, including tumour
necrosis factor inhibitors (such as etanercept, adalimu-
mab, infliximab and golimumab) or biologics with other
mechanisms of action such as abatacept, tocilizumab and
canakinumab.4–11
Adalimumab has a favourable benefit–risk profile in
children with JIA.1 6 12–14 A long-term, 4-period, phase
III study of up to 360 weeks of adalimumab treatment
with or without methotrexate (ClinicalTrials.gov Iden-
tifier: NCT00048542) was conducted in children with
JIA who had active disease and had failed NSAIDs.6
The results from the double-blind, placebo-controlled
period demonstrated that in patients who initially
responded to open-label adalimumab treatment, signif-
icantly fewer disease flares occurred in patients conti-
nuing to receive adalimumab compared with those
who switched to placebo; treatment response was sus-
tained during an additional 104 weeks of open-label
adalimumab treatment.
The objective of this follow-up analysis was to investigate
the long-term safety and efficacy of adalimumab with or
without methotrexate through up to 6 years of exposure
and to assess predictors of sustained disease control in
patients with polyarticular JIA through up to 6 years of
treatment.
METHODS
Study design and patients
The methods and results of the first 48 weeks of this
study have been previously published.6 Briefly, this was
a phase III, 4-period study that consisted of a 16-week
open-label adalimumab lead-in period followed by
a 32-week randomised, withdrawal, double-blind, pla-
cebo-controlled period and a 2-part, long-term exten-
s ion for up to 6.9 years (360 weeks; online
supplementary figure 1). Adalimumab was adminis-
tered based on body surface area (BSA; 24 mg/m2,
maximum of 40 mg every other week) during the
open-label lead-in and double-blind periods. Patients
with ≥30% improvement in the JIA ACR 30 response
at the end of the open-label lead-in period were eligi-
ble for randomisation for the double-blind period.
Patients completing the double-blind period were eli-
gible to enter into the 2-part long-term extension in
which patients received open-label adalimumab based
on BSA (24 mg/m2, maximum of 40 mg every other
week) for up to 44–136 weeks, and then fixed-dose
(FD) adalimumab (<30 kg, 20 mg every other week;
≥30 kg, 40 mg every other week) for up to 224 weeks.
Participants
Children aged 4–17 years with polyarticular-course juve-
nile rheumatoid arthritis (JRA) from any of the three JRA
onset subtypes (systemic, oligoarticular, polyarticular)
were eligible. This would correspond to the JIA eligible
categories of systemic, extended oligoarthritis and poly-
articular rheumatoid factor (RF positive and negative). In
addition, eligibility criteria included patients with active
disease (at least five active joints plus at least three joints
with limitation of motion) who had not responded ade-
quately or tolerated treatment with NSAIDs or
methotrexate.6 Patients were excluded if they had pre-
viously received treatment with other biological agents at
any time or were recently treated with intravenous immu-
noglobulin, cytotoxic agents, investigational agents, cor-
ticosteroids or disease-modifying antirheumatic drugs
(DMARDs) other than methotrexate.
Children were enrolled from 31 centres in 8 countries,
belonging to the Pediatric Rheumatology Collaborative
Study Group15 and the Pediatric Rheumatology Interna-
tional Trials Organization (PRINTO).16
Patients were stratified by baseline methotrexate use at
the beginning of the open-label lead-in period. Patients
in the non-methotrexate stratum either had never
received methotrexate or had discontinued methotrex-
ate at least 2 weeks before administration of the study
drug. Patients in the methotrexate stratum had received
methotrexate at a stable dosage of at least 10 mg/m2 per
week for the 3-month period before screening and con-
tinued to receivemethotrexate at the same dosage during
the open-label lead-in and double-blind periods. During
the extension periods, patients could change their meth-
otrexate dosing regimen.
Efficacy and safety outcomes
Safety was assessed by monitoring adverse events (AEs),
laboratory values, physical examination and vital signs
throughout the study and 70 days beyond the last dose
of adalimumab. Serious AEs were defined as events that
were fatal or life-threatening, required hospitalisation or
prolonged hospitalisation, resulted in congenital anom-
aly or persistent or significant disability/incapacity,
required medical or surgical intervention to prevent
a serious outcome, or other medically important condi-
tions (eg, miscarriage/spontaneous abortion, elective
abortion). AEs were coded using the Medical Dictionary
for Regulatory Activities version 12.1. Anti-adalimumab
antibodies (AAAs) were also assessed during the open-
label lead-in and double-blind periods; two AAA assess-
ments were done during the open-label extension at
weeks 12 and 16.
Long-term efficacy assessments over time included
the proportion of patients achieving JIA ACR 30/50/
70/90 response criteria defined as ≥30%, ≥50%, ≥70%
or ≥90% improvement from baseline in three of six
JIA core set variables and a worsening of >30% from
baseline in no more than one of the JIA core set
variables.17 The variables included Physician Global
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Assessment of disease activity (10 cm visual analogue
scale (VAS); 0=inactive; 10=maximum activity),
Patient or Parent Global Assessment of overall well-
being (10 cm VAS; 0=very good; 10=very poor), num-
ber of active joints (joints with swelling not due to
deformity or joints without swelling but with limita-
tion of passive movement, and with pain, tenderness
or both), number of joints with limitation of passive
movement, physical function using the Childhood
Health Assessment Questionnaire Disability Index
(CHAQ-DI; range, 0–3; 0=no disability and 3=severe
disability)18 19 and C reactive protein (CRP) as a
measure of inflammation.
Other assessed endpoints included Patient or Parent
Global Assessment of Pain (within last week; 10 cm VAS;
0=no pain; 10=severe pain), the proportion of patients
achieving 27-joint Juvenile Arthritis Disease Activity Score
(JADAS27) low disease activity (LDA, ≤3.8) and inactive
disease (ID, ≤1),20 mean change from baseline in
JADAS27 and CHAQ-DI, the proportion of patients
achieving JADAS27 clinical remission (defined as
JADAS27 ID sustained for ≥6 continuous months)20 and
time to first JADAS27 ID. JADAS27 consists of Physician
Global Assessment of overall disease activity (10 cm VAS),
Patient or Parent Global Assessment of overall well-being
(10 cm VAS), number of active joints assessed in 27 joints
and erythrocyte sedimentation rate (normalised to a 0–10
scale). JADAS27 is calculated as the sum of the scores,
yielding a score of 0–57.20
Predictor analyses
Predictor and regression tree analyses were used to iden-
tify baseline and postbaseline factors associated with the
achievement of JADAS27 clinical remission status. Tested
baseline variables were sex, race, weight, CRP, CHAQ-DI,
Physician Global Assessment of disease activity, Patient or
Parent Global Assessment of pain, Patient or Parent Global
Assessment of overall well-being, RF (positive vs negative),
swollen joint count, active joint count, tender joint count,
pain of passive movement joint count, limitation of passive
movement joint count, prior DMARD use, concurrent
methotrexate use and duration of JIA at baseline. Postbase-
line variables were JIA ACR 30/70/ 90 responses, JADAS27
LDA status and JADAS27 ID at weeks 4, 8, 12 and 16.
Statistical analysis
Efficacy analyses were performed in the intention-to-
treat population (any patient who received ≥1 dose of
study drug). Data were assessed as observed without
imputation (in patients with non-missing responses at
the assessed visit; patients who discontinued from the
study were considered as non-responders from that
point on) and using non-responder imputation (NRI;
for patients who did not enrol into double-blind trial,
discontinued from the study or had missing data for any
reason) as well as last observation carried forward
(LOCF). A subgroup analysis was performed stratifying
patients into those using concomitant methotrexate and
those not using methotrexate. The safety population
consisted of all patients exposed to adalimumab at any
point during the study. Rates of AEs are reported as
events per 100 patient-years (PY) of exposure. For the
predictor analysis, HR and 95% CI are reported. Uni-
variate Cox regression analysis model with each variable
as an independent variable was fit; p values at <0.05 level
were considered statistically significant.
Patient and public involvement
This research was done without any formal patient/
patient organisation involvement in study design, devel-
opment of patient-relevant outcomes, interpretation of
results, or the writing or editing of the manuscript.
RESULTS
Patients and baseline characteristics
A total of 171 patients were enrolled in the open-label
period; of these, 133 were randomised to receive adalimu-
mab or placebo during the double-blind period (figure 1).
Overall, 128 (75%) patients completed the double-blind
period and entered the long-term extension, with 62
(36%) patients completing it. Primary reasons for study
discontinuation were withdrawal of consent (n=20), lost to
follow-up (n=14) and ‘other’ reasons (n=22; figure 1). The
mean age at baseline was 11.3 years, 79% of patients were
female, mean disease duration was 3.8 years and mean
JADAS27 score was 22.5 (table 1). The 128 patients who
entered the long-term extension had similar baseline char-
acteristics as the overall population.
Safety
A total of 3605 (608.1/100 PY) AEs and 75 (12.7/100 PY)
serious AEs were reported through 592.8 PY of adalimu-
mab exposure. The incidence of AEs and serious AEs
possibly related to the study drug were 1394 (235.2/100
PY) and 19 (3.2/100 PY), respectively (table 2). Injection
site reactions (912 (153.8/100 PY)) and infections (880
(148.4/100 PY)) were the most common AEs. Twelve
serious infections in 11 (6%) patients were reported (3
events of appendicitis, 2 events of herpes zoster and 1
event each of bronchopneumonia, cervicitis, genital
herpes, pharyngitis, pneumonia, urinary tract infection
and viral infection); of these, 7 were categorised by the
investigator as possibly or probably related to the study
drug (3 (viral infection, herpes zoster, pharyngitis)
occurred during adalimumab plusmethotrexate regimen
and 4 (genital herpes, pneumonia, herpes zoster, bronch-
opneumonia) during or after adalimumab regimen). No
cases of congestive heart failure-related AEs, demyelinat-
ing disease, lupus-like syndrome, malignancies, tubercu-
losis or deaths were reported during the study. Twenty
patients (3.4/100 PY) discontinued from the study owing
to AEs (table 2). Injection site pain (28%), injection site
reaction (16%), headache (9%) and upper respiratory
tract infection (9%) were themost commonAEs reported
(online supplementary table 1).
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Incidence of AEs was similar among patients receiving
and not receiving concomitant methotrexate with the
exception of AEs leading to discontinuation (methotrex-
ate use, n=2 (2%) vs non-methotrexate use, n=7 (8%)) and
a few individual AEs, eg, worsening of juvenile arthritis and
oropharyngeal pain (online supplementary table 1).
The rate of serious AEs, severe AEs, AEs leading to
discontinuation of study drug and serious infectious AEs
Figure 1 Patient disposition. *Not randomised at week 16 (n=12), sponsor decision (n=2), non-responder at week 16 (n=1).
†Sponsor request/decision (n=2), randomised in error (n=1). ‡Site not participating in the extension (n=5), remission (n=1). §Not
known (n=13). AE, adverse event; BSA, body surface area; DB, double-blind; FD, fixed- dose; MTX, methotrexate.
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were <10% in both AAA-negative and -positive groups
during the open-label lead-in period and double-blind
period (online supplementary tables 2 and 3). The rates
of AEs leading to discontinuation of study drug and
infectious AEs were lower in the AAA-positive groups
than in the AAA-negative groups. Injection site reactions
reported as AEs were similar among the two groups. Over-
all, no increased safety risk was observed in patients who
were AAA positive versus those who were AAA negative in
the presence or absence of methotrexate. Because AAAs
were not assessed beyond week 16 of the open-label
extension, no analysis could be done past the double-
blind period.
Efficacy
JIA ACR 30 was achieved as early as week 2 of the lead-in
period (103/167 patients–observed analysis: 62%; NRI
analysis: 60%). In the observed analysis, the majority of
patients had achieved JIA ACR 30 (90/94 (96%)), JIA
ACR 50 (88/94 (94%)), JIA ACR 70 (84/94 (89%)) and
JIA ACR 90 (62/94 (66%)) responses (NRI analysis: 36%
to 53%) at week 104 (year 2; figure 2).
Similarly, the majority of patients achieved JADAS27
LDA (observed analysis: 73%; NRI analysis: 44%) at
week 104 (year 2); JADAS27 ID was achieved by 43% of
patients in the observed analysis and 26% in the NRI
analysis at week 104 (figure 2). The response rates were
generally maintained through week 312 (year 6; figure 2).
When stratified by concomitant methotrexate use,
there was a trend for numerically higher JIA ACR 30/
50/70/90 response (online supplementary figure 2) and
higher rate of JADAS27 LDA and JADAS27 ID (online
supplementary figure 3A) among patients receiving con-
comitant methotrexate versus those not receiving









Age, years 11.3 (3.5) 11.3 (3.6)
Disease duration, years 3.8 (3.9)† 3.7 (3.6)‡
Female, n (%) 135 (78.9) 98 (76.6)
White, n§ (%) 157 (95.2) 121 (96.0)
Body weight, kg 42.2 (18.8) 43.5 (19.5)
Rheumatoid factor
positive, n¶ (%)




44 (25.7) 36 (28.1)
Prior methotrexate use,
n (%)
103 (60.2) 83 (64.8)
Tender joint count 11.4 (12.4) 12.0 (12.8)
Swollen joint count 14.8 (9.4) 14.9 (9.1)
Pain on passive motion
joint count
10.3 (11.7) 9.5 (10.4)
Limitation of passive
motion joint count
13.5 (9.2) 13.4 (9.4)
Active joint count 17.2 (10.4) 17.2 (10.3)
CRP, mg/dL 2.6 (4.1)§ 2.4 (4.1)¶




5.9 (1.8) 5.8 (1.8)
Patient or Parent Global
Assessment of overall
well-being**
4.8 (2.3)§ 4.8 (2.3)¶
Patient or Parent Global
Assessment of pain††





1.1 (0.7) 1.0 (0.7)
Tender joint count, pain on passive motion joint count and limitation
of passive motion joint count based on 75 joints; swollen joint count
based on 66 joints.





||Elevated CRP defined as >0.0287 mg/dL.
#0–10 cm visual analogue scale (0=inactive; 10=maximum activity).
**0–10 cm visual analogue scale (0=very good; 10=very poor).
††0–10 cm visual analogue scale (0=no pain; 10=very severe pain).
‡‡Mean rating of 8 category scores (0=no difficulty to perform
activity; 3=complete inability to perform activity).
CRP, C reactive protein; DMARDs, disease-modifying antirheumatic
drugs.
Table 2 Rates of adverse events




Any AE 3605 (608.1)
AE possibly drug related 1394 (235.2)
Serious AE 75 (12.7)
Serious AE possibly drug related 19 (3.2)
Severe AE 52 (8.8)
AE leading to discontinuation 20 (3.4)
Infection 880 (148.4)
Serious infection* 12 (2.0)
Opportunistic infection† 2 (0.3)
Tuberculosis 0
Malignancy 0
Injection site reaction 912 (153.8)
Death 0
*Twelve serious infections were reported in 11 patients: 3 events of
appendicitis, 2 events of herpes zoster and 1 event each of
bronchopneumonia, cervicitis, genital herpes, pharyngitis, pneu-
monia, urinary tract infection and viral infection.
†One event of oral candidiasis and one event of cytomegalovirus
infection.
AE, adverse event; PY, patient-years.
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Figure 2 Percentage of patients achieving JIA ACR 30/50/70/90, JADAS27 LDA and JADAS27 inactive disease over time. (A)
Observed and (B) NRI analyses. JADAS27 LDA, ≤3.8; JADAS27 inactive disease, ≤1. For observed analysis, n values are shown for
weeks 0, 104, 200 and 312; for NRI analysis, N=171. JADAS27, 27-joint Juvenile Arthritis Disease Activity Score;
JIA ACR 30/50/70/90, 30%, 50%, 70%, or 90% improvement in the Juvenile Idiopathic Arthritis American College of Rheuma-
tology response; LDA, low disease activity; NRI, non-responder imputation.
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methotrexate in the NRI analysis but not in the observed
analysis.
JIA improved during the study as assessed by a decrease
in mean JADAS27 score of 22.5 (n=170) at baseline to 2.5
(n=30; mean reduction of −16.7 (n=29)) by week 312 in
observed analysis and to 7.5 (mean reduction of −14.9) in
LOCF analysis (figure 3). A total of 63 (37%) patients
achieved JADAS27 clinical remission (ie, sustained
JADAS27 ID ≥6 continuous months) during the study;
the median time to reach JADAS27 clinical remission
was 216 weeks (4.2 years). Of the 106 patients completing
the BSA dosing period and entering the FD dosing period
of the extension, adalimumab dose was increased in half
(n=53) and remained the same (n=50) or was decreased
(n=3) in the other half. JIA ACR response rates were
maintained during the extension periods, regardless of
dose change.
When stratified by concomitant methotrexate use,
mean JADAS27 and CHAQ-DI were approximately two-
fold higher (ie, worse) throughout the study among
patients not receiving concomitant methotrexate versus
those receiving methotrexate in the LOCF analyses,
whereas mean values were similar in the observed ana-
lyses (online supplementary figure 3B).
Predictor analysis
Early JIA ACR and JADAS27 LDA and ID responses (ie, at
weeks 4, 8, 12 and 16) were the only predictors of
JADAS27 clinical remission (ie, sustained JADAS27 ID
for ≥6 continuous months; figure 4). Achievement of JIA
ACR 90 at week 12 was most predictive of later achieve-
ment JADAS27 clinical remission (online supplementary
figure 4).
DISCUSSION
This long-term open-label extension study demonstrated
that adalimumab was well tolerated and effective among
children with polyarticular JIA through 6 years of expo-
sure with or without background methotrexate therapy
but was associated with a relatively low treatment reten-
tion rate. No new safety signals were identified in this
study. Serious AEs and serious infections were within the
range of those reported for other pediatric populations
treated with adalimumab.21 Overall, the adalimumab
safety profile in this study was consistent with that of
adult populations.22 No increased safety risk was observed
in patients who were AAA positive versus those who were
AAA negative in the presence or absence of
methotrexate.
These findings were also consistent with data from the
real-world STRIVE registry in patients with active polyar-
ticular JIA.23 24 In the 7-year interim analysis of STRIVE,
the rate of serious AEs was 7.2/100 PY and the rate of
serious infections was 2.0/100 PY with 1855.5 PY of adali-
mumab exposure (± methotrexate). Similar results were
demonstrated in the German BiKeR registry in patients
with polyarticular JIA (serious AEs, 11.0/100 PY; serious
infections, 5.5/100 PY).25
This study enrolled children with JIA who failed pre-
vious NSAID treatment or methotrexate monotherapy,
and had active disease at baseline. After open-label adali-
mumab treatment was initiated, clinical responses were
achieved as early as week 2 and maintained throughout
the study with more than one-third of patients achieving
JADAS27 clinical remission (ie, sustained JADAS27 ID ≥6
continuous months) after 4 years of treatment. The
results of the conservative NRI analysis, as opposed to
Figure 3 Mean (A) JADAS27 and (B) CHAQ-DI over time, observed and LOCF analyses. N values for observed analysis are shown
for weeks 0, 104, 200 and 312. Dotted lines represent JADAS27 LDA (≤3.8) and JADAS ID (≤1) cut-offs. CHAQ-DI, Childhood
Health Assessment Questionnaire Disability Index; ID, inactive disease; JADAS27, 27-joint Juvenile Arthritis Disease Activity
Score; LDA, low disease activity; LOCF, last observation carried forward; NRI, non-responder imputation.
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the observed analysis, and their interpretation were
impacted by the high study discontinuation rate.
Although the retention rate of treatment was relatively
low, it is in line with other long-term JIA extension stu-
dies; 36% of patients completed a 7-year abatacept trial,26
30% completed a 204-week (4-year) infliximab trial27 and
38% completed 7 years in an etanercept study.28 These
low retention rates observed in many JIA trials highlight
the need to have alternative therapies or different treat-
ment strategies, such as the treat-to-target, to better
achieve long-term disease control.29 Of note, in this
study, most discontinuations during the extension period
were due to withdrawal of consent (n=18), lost to follow-
up (n=13) and other (n=19, including one patient in
remission) versus AEs (n=6) or lack of efficacy (n=7);
however, all discontinuations are counted as lack of
response in the NRI analysis to provide a conservative
estimate in line with the intention-to-treat principles.
The findings of this study also indicated that early clin-
ical response predicted achievement of JADAS27 clinical
Figure 4 Baseline and postbaseline (JIA ACR responses at weeks 4, 8, 12 and 16) predictors of JADAS27 clinical remission
(JADAS27 ≤1 sustained for ≥6 continuous months). BL, baseline; ID, inactive disease; JADAS27, 27-joint Juvenile Arthritis Disease
Activity Score; JIA ACR 30/50/70/90, 30%, 50%, 70%or 90% improvement in the Juvenile Idiopathic Arthritis American College of
Rheumatology response; LDA, low disease activity; LOM, limitation of movement; wk, week.
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remission. In a previous study, JIA ACR 70 response at
4 months was a predictor of disease remission in patients
with methotrexate-refractory JIA who were receiving
etanercept.30 Similarly, a study in patients with polyarti-
cular JIA receiving methotrexate with or without etaner-
cept and prednisolone demonstrated that JIA ACR 70
response at 4 months was a strong predictor of achieve-
ment of clinical ID.31 Similar results have been demon-
strated in rheumatoid arthritis studies in which early
response to treatment predicted remission or good clin-
ical response long term.32–34 Furthermore, a poor
response (assessed by JIA ACR 30 and 70) to 6-month
treatment with methotrexate in patients with polyarticu-
lar JIA was associated with higher disability, antinuclear
antibody negativity, and longer disease duration in the
PRINTO trial.35 An analysis of the BiKeR registry demon-
strated that earlier treatment with a biological agent
(within 2 years of symptom onset) was associated with
better disease control and drug-free remission.36 Taken
together, these results suggest that early response to treat-
ment is associated with disease remission in patients with
JIA, and therapy adjustments are warranted early on in
patients who fail to respond. Of note, RF negativity was
not a predictor of achieving remission in our analysis,
although RF-positive polyarticular JIA has been asso-
ciated with lower rates of remission than other JIA forms
in the past.37–39
The strengths of this study include long follow-up dura-
tion, inclusion of response results for both BSA and FD
dosing regimens, and the consistency of efficacy and safety
results throughout the years in an established population
(polyarticular forms of JIA). Other strengths include using
both JIA ACR response criteria and JADAS as efficacy
measures to complement each other and measurement
of more stringent levels of response (such as JADAS27 ID
and JADAS27 clinical remission). The 128 patients who
entered the long-term extension had similar baseline char-
acteristics as the overall population, and therefore were
representative of the overall patient population. In com-
mon with other JIA long-term extension studies, a major
limitation was the low retention rate, with many patients
discontinuing during the long-term extension period.
Additionally, the sample size was not large enough for
the evaluation of rare AEs, no radiological data were col-
lected, and there may be a potential dropout bias.
Conclusions
The results of this study show that long-term adalimumab
therapy is well tolerated and effective in patients with
polyarticular JIA. However, the low treatment retention
rate should be noted when assessing these results. Over-
all, our results support the use of adalimumab as a therapy
option for patients with active polyarticular JIA.
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